IL4I1は,AHRを活性化し,腫瘍の進行を促進する代謝免疫チェックポイントです
Ahmed Sadik1, Luis F Somarribas Patterson2, Selcen Öztürk3
1DKTK Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Faculty of Bioscience, Heidelberg University, 69120 Heidelberg, Germany.
Cell
|August 21, 2020
まとめ
アリル炭水化物受容体 (AHR) を活性化し,がんの進行と免疫抑制を促進します. IL4I1を阻害することで 癌治療の新たな戦略が生まれます
科学分野:
- 免疫学
- 腫瘍学
- 生物化学
背景:
- アリル炭化水素受容体 (AHR) のトリプトファン・カタボライトによる活性化は,腫瘍の悪性増殖を促進し,抗腫瘍免疫を抑制する.
- AHR標的遺伝子の文脈特異性は,ヒトの癌におけるAHR活動に関する包括的な研究を妨げています.
研究 の 目的:
- 様々なヒトがんにおけるAHR活動に関連した新しい酵素を特定する.
- 癌の進行と免疫回避におけるIL4I1の役割を調査する.
- 癌治療における潜在的な治療標的としてIL4I1を調査する.
主な方法:
- パン組織 AHR シグネチャーを得るための自然言語処理.
- IDO1とTDO2と比較したAHR活動とのIL4I1関連性の分析
- 慢性リンパ球性白血病 (CLL) のマウスモデルを用いたin vivo研究.
- 患者の生存と免疫反応に対するIL4I1の影響の評価
主要な成果:
- IL4I1は,IDO1とTDO2を上回る32種類の腫瘍における頻繁なAHR活動マーカーとして特定されました.
- IL4I1はインドル代謝産物とキヌレン酸を通してAHRを活性化させ,膠原腫患者の生存期間を短縮させる.
- IL4I1はがん細胞の運動性を促進し,適応免疫を抑制し,マウスのCLLの進行を悪化させる.
- 免疫チェックポイント阻害 (ICB) は,IDO1とIL4I1の両方を誘導し,IL4I1がICBとIDO1の併用抑制療法の限られた有効性を説明する可能性があることを示唆しています.
結論:
- IL4I1は,AHR主導の腫瘍悪性および免疫抑制の重要な媒介です.
- IL4I1阻害は様々な癌に対する 新しく有望な治療戦略です
- IL4I1の役割を理解することは,がん免疫療法の成果を改善するために不可欠です.
関連する概念動画
PI3K/mTOR/AKT Signaling Pathway
5.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.0K
T Cell Types and Functions
1.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.9K
lncRNA - Long Non-coding RNAs
9.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
Tumor Immunotherapy
1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
The JAK-STAT Signaling Pathway
11.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.2K


